MAIA PHARMS INC
PharmaMAIA PHARMS INC is a pharmaceutical company focused on Neurology, Infectious Disease, Dermatology. Key products include SODIUM PHENYLACETATE AND SODIUM BENZOATE.
MAIA PHARMS INC's Key Drugs
MAIA PHARMS INC's core commercial portfolio centers on SODIUM PHENYLACETATE AND SODIUM BENZOATE, ANGIOMAX RTU, spanning Neurology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
MAIA PHARMS INC's Recent FDA Approvals
MAIA PHARMS INC secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
MAIA PHARMS INC's Therapeutic Areas
MAIA PHARMS INC's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MAIA PHARMS INC's Top Competitors
MAIA PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MAIA PHARMS INC Pipeline Snapshot
Active clinical trials for MAIA PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SODIUM PHENYLACETATE AND SODIUM BENZOATE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2017-05-08
- Latest
- 2024-11-21
- Applications
- 10